XML 62 R25.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 29, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Revenues Under Collaboration Agreement | Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):
| Year Ended December 31,
| 2017 |  | 2016 |  | 2015
Royalties accruing to GSK | $ | 12,413 |  |  | $ | 4,334 |  |  | $ | 1,029 |
Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):
| Year Ended December 31,
| 2017 |  | 2016
Milestones achieved | $ | 45,000 |  |  | $ | 20,000 |
Amortization of upfront payments and deferred milestone | 18,531 |  |  | 13,284 |
Royalty revenue | 3,831 |  |  | 175 |
Development cost reimbursements | 4,417 |  |  | — |
Product supply agreement revenue | 6,390 |  |  | 1,612 |
Cost of supplied product | (6,390 | ) |  | (1,555 | )
Royalty payable to GSK on net sales by Ipsen | (1,987 | ) |  | (264 | )
Collaboration revenues under the collaboration agreement with Ipsen | $ | 69,792 |  |  | $ | 33,252 |
Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):
| Year Ended December 31,
| 2017 |  | 2016 |  | 2015
Collaboration revenues: |  |  |  |  |
Royalty revenues on ex-U.S. sales of COTELLIC | $ | 6,398 |  |  | $ | 2,827 |  |  | $ | 14 |
U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses | $ | (2,140 | ) |  | $ | 8,771 |  |  | $ | (16,600 | )
Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):
| Year Ended December 31, 2017
Amortization of upfront payment | $ | 10,377 |
Development cost reimbursements | 4,320 |
Product supply agreement revenue | 82 |
Collaboration revenues under the collaboration agreement with Takeda | $ | 14,779 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration